Pacific biosciences of california, inc. PACB.US Overview
PACB AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
PACB Current Performance
-3.62%
Pacific biosciences of california, inc.
-0.34%
Avg of Sector
-1.60%
S&P500
PACB Key Information
PACB Revenue by Segments
Browsing restrictions can be lifted for a fee.
PACB Net Income
Browsing restrictions can be lifted for a fee.
PACB Cash Flow
Browsing restrictions can be lifted for a fee.
PACB Profit Margin
Browsing restrictions can be lifted for a fee.
PACB PE Ratio River
Browsing restrictions can be lifted for a fee.
PACB Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
PACB Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
PACB Profile
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Price of PACB
PACB FAQ
When is PACB's latest earnings report released?
The most recent financial report for Pacific biosciences of california, inc. (PACB) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PACB's short-term business performance and financial health. For the latest updates on PACB's earnings releases, visit this page regularly.
What is the operating profit of PACB?
According to the latest financial report, Pacific biosciences of california, inc. (PACB) reported an Operating Profit of -447.63M with an Operating Margin of -1,204.84% this period, representing a decline of 449.7% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is PACB's revenue growth?
In the latest financial report, Pacific biosciences of california, inc. (PACB) announced revenue of 37.15M, with a Year-Over-Year growth rate of -4.27%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does PACB have?
As of the end of the reporting period, Pacific biosciences of california, inc. (PACB) had total debt of 699.11M, with a debt ratio of 0.81. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does PACB have?
At the end of the period, Pacific biosciences of california, inc. (PACB) held Total Cash and Cash Equivalents of 59.2M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does PACB go with three margins increasing?
In the latest report, Pacific biosciences of california, inc. (PACB) did not achieve the “three margins increasing” benchmark, with a gross margin of -3.7%%, operating margin of -1,204.84%%, and net margin of -1,146.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess PACB's profit trajectory and future growth potential.
Is PACB's EPS continuing to grow?
According to the past four quarterly reports, Pacific biosciences of california, inc. (PACB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of PACB?
Pacific biosciences of california, inc. (PACB)'s Free Cash Flow (FCF) for the period is -45.45M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 42.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of PACB?
The latest valuation data shows Pacific biosciences of california, inc. (PACB) has a Price-To-Earnings (PE) ratio of -0.5 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.